Mate Extract Supplementation Reduces Body and Abdominal Fat in Obese Korean Subjects

Chonbuk National University Hospital0 sites30 target enrollmentOctober 2011

ConditionsObesity

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Obesity
Sponsor: Chonbuk National University Hospital
Enrollment: 30
Primary Endpoint: Changes in body and abdominal fat
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Obesity is a major health issue worldwide; there is a constant raise in obesity related death each year.

Detailed Description

The primary aim of the study was to investigate the effect of Mate extracts in Korean subjects on body fat and abdominal fat, double blind, placebo-controlled clinical trial. Thirty obesity subjects with BMI ≥ 25 kg/㎡ and waist-hip ratio (WHR)≥ 0.90 for men and ≥ 0.85 for women were for 12 weeks.

Registry

clinicaltrials.gov

Start Date

October 2011

End Date

March 2012

Last Updated

13 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Chonbuk National University Hospital

Responsible Party

Principal Investigator

Min-Gul Kim, MD

Clinical Assistant Professor

Chonbuk National University Hospital

Eligibility Criteria

Inclusion Criteria

•Volunteers aged 19 to 65 years
•25 kg/m2 ≤ BMI ≥35 kg/m2
•Ability to give informed consent

Exclusion Criteria

•Significant variation in weight (more 10%) in the past 3 month
•Cardiovascular disease, neurologic or psychiatric disease, renal, pulmonary and hepatic abnormalities
•History of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease (Crohn's disease) or gastrointestinal surgery (a caesum or enterocele surgery are included)
•Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the sutdy
•Allergic or hypersensitive to any of the ingredients in the test products
•Pregnancy or breast feeding
•Used antipsychosis drugs therapy within past 2 months
•History of alcohol or substance abuse (21 units/week over)
•Participation in any other clinical trials within past 3 months

Outcomes

Primary Outcomes

Changes in body and abdominal fat

Time Frame: body fat: baseline, 6 weeks and 12 weeks, abdominal fat of CT: baseline and 12 weeks

Secondary Outcomes

Changes in anthropometric parameters(weight, BMI, waist and hip circumference)(baseline, 6 weeks and 12 weeks)
Changes in blood lipid profile(total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, free fatty acid)(baseline, 6 weeks and 12 weeks)